Novartis counsel warns: ‘Don’t let AI develop without our input’

The best use of AI can—in the most extreme cases—mean the difference between life and death, according to Carol Fang, global head of IP platforms at Novartis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

29 October 2025 With fraudsters exploiting new technologies, the company’s Kenya Williams explains why vigilant enforcement is money well spent to maintain a ‘clean’ brand.

Americas

LSPN panel unpacks critical IP risks in deal-making

23 October 2025 Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.

More features

Squires: ‘Inherited patent backlog was an absolute dumpster fire’

Delegates descend upon Washington, DC for AIPLA Annual Meeting

Novo Nordisk counters rival with $9bn bid for obesity drug developer

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

China trademarks rankings reveal new entries, hidden gems and big brands

Edwards defends key heart valve product from infringement threat

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

Novartis counsel warns: ‘Don’t let AI develop without our input’

More on this story

Editor's picks

Editor's picks

More features